Inhibition of mutated BRAF in melanoma

N Engl J Med. 2010 Dec 2;363(23):2261; author reply 2261-2. doi: 10.1056/NEJMc1010755.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Drug Resistance, Neoplasm
  • Genes, ras
  • Humans
  • Indoles / administration & dosage*
  • Isoquinolines
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / secondary
  • Mitogen-Activated Protein Kinases / metabolism
  • Mutation
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Sulfonamides / administration & dosage*
  • Vemurafenib

Substances

  • 1-isoquinolyl-(3-(trifluoromethyl)phenyl)methanone
  • Antineoplastic Agents
  • Indoles
  • Isoquinolines
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Mitogen-Activated Protein Kinases